Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-Part Proof-of-Concept Study: An Open-Label Dose-Ranging Phase (Part A) Followed by a Randomized, Single-Blind, Placebo-Controlled Phase (Part B) Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia

NCT04780841 is registered in ClinicalTrials.gov with Ardelyx as lead sponsor.

NCT NCT04780841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04780841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-Part Proof-of-Concept Study: An Open-Label Dose-Ranging Phase (Part A) Followed by a Randomized, Single-Blind, Placebo-Controlled Phase (Part B) Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia
Lead sponsor
Ardelyx
Phase
Phase 2
Overall status
Completed
Start date
January 11, 2021
Completion date
March 3, 2022
Enrollment
109 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hyperkalemia